Cargando…

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly selective for DPP-4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4 inhibitors elevate plasma concentra...

Descripción completa

Detalles Bibliográficos
Autor principal: Gallwitz, Baptist
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047961/
https://www.ncbi.nlm.nih.gov/pubmed/21437082